Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2011 2
2012 2
2013 2
2019 3
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
Overview of the Mutational Landscape in Primary Myelofibrosis and Advances in Novel Therapeutics.
Gilani JA, Ashfaq MA, Mansoor AE, Abdul Jabbar A, Siddiqui T, Khan M. Gilani JA, et al. Asian Pac J Cancer Prev. 2019 Jun 1;20(6):1691-1699. doi: 10.31557/APJCP.2019.20.6.1691. Asian Pac J Cancer Prev. 2019. PMID: 31244289 Free PMC article. Review.
Primary Myelofibrosis is a BCR-ABL negative myeloproliferative neoplasm with a variety of hematological presentations, including thrombosis, bleeding diathesis and marrow fibrosis. ...These include JAK inhibitors like ruxolitinib, heat shock protein-90 inhibitors li
Primary Myelofibrosis is a BCR-ABL negative myeloproliferative neoplasm with a variety of hematological presentations, includi
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2020 Feb;152:104609. doi: 10.1016/j.phrs.2019.104609. Epub 2019 Dec 17. Pharmacol Res. 2020. PMID: 31862477 Review.
Eight drugs are employed in the treatment of non-malignancies: fedratinib, myelofibrosis; ruxolitinib, myelofibrosis and polycythemia vera; fostamatinib, chronic immune thrombocytopenia; baricitinib, rheumatoid arthritis; sirolimus, renal graft vs. host disease; nin …
Eight drugs are employed in the treatment of non-malignancies: fedratinib, myelofibrosis; ruxolitinib, myelofibrosis and polyc …
Properties of FDA-approved small molecule protein kinase inhibitors.
Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2019 Jun;144:19-50. doi: 10.1016/j.phrs.2019.03.006. Epub 2019 Mar 13. Pharmacol Res. 2019. PMID: 30877063 Review.
Most of the small molecule inhibitors (45) interact directly with the protein kinase domain. In contrast, sirolimus, temsirolimus, and everolimus are larger molecules (MW 1000) that bind to FKBP-12 to generate a complex that inhibits mTOR (mammalian target of rapamycin). . …
Most of the small molecule inhibitors (45) interact directly with the protein kinase domain. In contrast, sirolimus, temsirolimus, and ev
Emerging targeted therapies in myelofibrosis.
Barosi G. Barosi G. Expert Rev Hematol. 2012 Jun;5(3):313-24. doi: 10.1586/ehm.12.17. Expert Rev Hematol. 2012. PMID: 22780211 Review.
Conventional drugs for myelofibrosis are driven by clinical needs, primarily anemia and splenomegaly. ...JAK2 ATP competitive inhibitors (ruxolitinib, lestaurtinib, SAR302503, SB1518 and CYT387) or drugs that indirectly inhibit the JAK-STAT pathway (everolimus) have …
Conventional drugs for myelofibrosis are driven by clinical needs, primarily anemia and splenomegaly. ...JAK2 ATP competitive inhibit …
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.
Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L, Biamonte F, Bartalucci N, Gattoni E, Lupo ML, Finazzi G, Pancrazzi A, Antonioli E, Susini MC, Pieri L, Malevolti E, Usala E, Occhini U, Grossi A, Caglio S, Paratore S, Bosi A, Barbui T, Vannucchi AM; AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators. Guglielmelli P, et al. Blood. 2011 Aug 25;118(8):2069-76. doi: 10.1182/blood-2011-01-330563. Epub 2011 Jul 1. Blood. 2011. PMID: 21725052 Free PMC article. Clinical Trial.
We conducted a phase 1/2 study with everolimus, an mTOR inhibitor, in 39 high- or intermediate-risk primary or postpolycythemia vera/postessential thrombocythemia myelofibrosis subjects. ...These results provide proof-of-concept that targeting mTOR pathway in …
We conducted a phase 1/2 study with everolimus, an mTOR inhibitor, in 39 high- or intermediate-risk primary or postpolycythemi …
Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
Bartalucci N, Guglielmelli P, Vannucchi AM. Bartalucci N, et al. Clin Lymphoma Myeloma Leuk. 2013 Sep;13 Suppl 2:S307-9. doi: 10.1016/j.clml.2013.07.011. Clin Lymphoma Myeloma Leuk. 2013. PMID: 24290217 Review.
Patients with PV and primary myelofibrosis hematopoietic progenitors were significantly more sensitive to everolimus compared with healthy control subjects. ...Similar data were obtained using a dual PI3K/mTOR inhibitor, BEZ235, with activity that was also sh …
Patients with PV and primary myelofibrosis hematopoietic progenitors were significantly more sensitive to everolimus co …
Breakthroughs in myeloproliferative neoplasms.
Santos FP, Verstovsek S. Santos FP, et al. Hematology. 2012 Apr;17 Suppl 1:S55-8. doi: 10.1179/102453312X13336169155574. Hematology. 2012. PMID: 22507780 Review.
Currently, there are several JAK2 inhibitors in clinical trials for patients with MPNs, particularly for patients with myelofibrosis (MF). These drugs act by blocking the proliferation of neoplastic cells by disrupting the JAK2-STAT signaling and by abrogating inflammatory …
Currently, there are several JAK2 inhibitors in clinical trials for patients with MPNs, particularly for patients with myelofibrosis
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O'Brien S, Andreeff M, Giles FJ. Yee KW, et al. Clin Cancer Res. 2006 Sep 1;12(17):5165-73. doi: 10.1158/1078-0432.CCR-06-0764. Clin Cancer Res. 2006. PMID: 16951235 Free article. Clinical Trial.
A phase I/II study was done to determine safety and efficacy of everolimus in patients with relapsed or refractory hematologic malignancies. EXPERIMENTAL DESIGN: Two dose levels (5 and 10 mg orally once daily continuously) were evaluated in the phase I portion of this stud …
A phase I/II study was done to determine safety and efficacy of everolimus in patients with relapsed or refractory hematologic malign …
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
Bogani C, Bartalucci N, Martinelli S, Tozzi L, Guglielmelli P, Bosi A, Vannucchi AM; Associazione Italiana per la Ricerca sul Cancro AGIMM Gruppo Italiano Malattie Mieloproliferative. Bogani C, et al. PLoS One. 2013;8(1):e54826. doi: 10.1371/journal.pone.0054826. Epub 2013 Jan 31. PLoS One. 2013. PMID: 23382981 Free PMC article.
Recent clinical trials with JAK2 inhibitors showed significant improvements in splenomegaly and constitutional symptoms in patients with myelofibrosis but meaningful molecular responses were not documented. ...JAK2 inhibitors produced similar antiproliferative effects in M …
Recent clinical trials with JAK2 inhibitors showed significant improvements in splenomegaly and constitutional symptoms in patients with …
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.
Tefferi A, Abdel-Wahab O, Cervantes F, Crispino JD, Finazzi G, Girodon F, Gisslinger H, Gotlib J, Kiladjian JJ, Levine RL, Licht JD, Mullally A, Odenike O, Pardanani A, Silver RT, Solary E, Mughal T. Tefferi A, et al. Blood Cancer J. 2011 Mar 4;1(3):e7. doi: 10.1038/bcj.2011.4. Blood Cancer J. 2011. PMID: 23471017 Free PMC article.
We provide a detailed overview of new mutations with putative epigenetic effects (TET oncogene family member 2 (TET2), additional sex comb-like 1 (ASXL1), isocitrate dehydrogenase (IDH) and enhancer of zeste homolog 2 (EZH2)) and an update on treatment with Janus kinase (JAK) inh …
We provide a detailed overview of new mutations with putative epigenetic effects (TET oncogene family member 2 (TET2), additional sex comb-l …